​Principal Investigator: Dr. Yi Lin

Disease: Multiple Myeloma

Research Description: CAR-T therapy has revolutionized treatment for relapsed refractory multiple myeloma (RRMM), however, it is not curative, and relapse still occurs. This could be due to cancer cells going dormant via a process called senescence, allowing them to survive CAR-T treatments. This Phase II trial examines adding a combination of dasatinib and quercetin, two drugs that target senescent cells specifically, to CAR-T therapy in RRMM patients.

Funding Partners: Goldman Philanthropic Partnerships

Initial CWR Funding Role: Supplemental